Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.
A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.
The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.